Downregulation of LncRNAH19 and MiR-675 promotes migration and invasion of human hepatocellular carcinoma cells through AKT/GSK-3β/Cdc25A signaling pathway

Abstract

LncRNAH19 has been implicated as having both oncogenic and tumor suppression properties in cancer. LncRNAH19 transcripts also serve as a precursor for miR-675. However, it is unknown whether LncRNAH19 and miR-675 are involved in the migration and invasion of hepatocellular carcinoma (HCC) cells. The purpose of this study was to investigate the effect and mechanism of LncRNAH19 and miR-675 on migration and invasion of HCC cells. The migration and invasion of HCC cells were measured by Transwell migration and invasion assays after transfection of HCC cells with miR-675 inhibitors and LncRNAH19siRNA. The levels of LncRNAH19 and miR-675 were detected by quantitative reverse transcriptase real-time polymerase chain reaction (qRT-PCR), and the protein expression of AKT, GSK-3β and Cdc25A by Western blotting analysis. The expression levels of LncRNAH19 and miR-675 were higher in MHCC-97H cells than in L02, Huh-7 and HepG2 cells. Transwell migration assay revealed that the miR-675 inhibitor and LncRNAH19siRNA could significantly increase the migration of HCC cells (P<0.01) as compared with the control group. Transwell invasion assay demonstrated that the miR-675 inhibitor and LncRNAH19siRNA could significantly increase the invasion of HCC cells (P<0.01) as compared with the control group. Western blotting analysis showed that the expression levels of AKT and Cdc25A were significantly increased (P<0.05), and the expression level of GSK-3β was significantly decreased (P<0.05) after treatment with miR-675 inhibitors and LncRNAH19siRNA as compared with the control group. These findings suggested that inhibition of LncRNAH19 and miR-675 expression can promote migration and invasion of HCC cells via AKT/GSK-3β/Cdc25A signaling pathway.

Keywords

LncRNAH19 / miR-675 / hepatocellular carcinoma / migration / invasion / AKT/GSK-3β/Cdc25A signaling pathway

References

[1] FerlayJ, ShinHR, BrayF, et al.. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 2010, 127(12): 2893-2917

[2] Esquela-KerscherA, SlackFJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer, 2006, 6(4): 259-269

[3] HuangS, HeX. The role of microRNAs in liver cancer progression. Br J Cancer, 2011, 104(2): 235-240

[4] WongQW, ChingAK, ChanAW, et al.. MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res, 2010, 16(3): 867-875

[5] YaoJ, LiangL, HuangS, et al.. MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology, 2010, 51(3): 846-856

[6] XiaH, OoiLL, HuiKM. MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma. PLoS One, 2012, 7(9): e44206

[7] HuarteM, RinnJL. Large non-coding RNAs: missing links in cancer?. Hum Mol Genet, 2010, 19R2: 152-161

[8] LaiMC, YangZ, ZhouL, et al.. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol, 2012, 29(3): 1810-1816

[9] GengYJ, XieSL, LiQ, et al.. Large intervening non-coding RNAHOTAIR is associated with hepatocellular carcinoma progression. J Int Med Res, 2011, 39(6): 2119-2128

[10] MatoukIJ, DeGrootN, MezanS, et al.. The H19 non-coding RNA is essential for human tumor growth. PLoS One, 2007, 2(9): e845

[11] WuJ, QinY, LiB, et al.. Hypomethylated and hypermethylated profiles of H19DMR are associated with the aberrant imprinting of IGF2 and H19 in human hepatocellular carcinoma. Genomics, 2008, 91(5): 443-450

[12] ChenCL, LpSM, ChengD, et al.. Loss of imprinting of the IGF-II and H19 genes in epithelial ovarian cancer. Clin Cancer Res, 2000, 6(2): 474-479

[13] NakagawaH, ChadwickRB, PeltomakiP, et al.. Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc Natl Acad Sci USA, 2001, 98(2): 591-596

[14] CaiX, CullenBR. The imprinted H19 noncoding RNA is a primary micro-RNA precursor. RNA, 2007, 13(3): 313-316

[15] WendelHG, De StanchinaE, FridmanJS, et al.. Survival signaling by Akt and eIF4E in oncogenesis and cancer therapy. Nature, 2004, 428(6980): 332-337

[16] CrossDA, AlessiDR, CohenP, et al.. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature, 1995, 378(6559): 785-789

[17] KangT, WeiY, HonakerY, et al.. GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell, 2008, 13(1): 36-47

[18] KristjánsdóttirK, RudolphJ. Cdc25 phosphatases and cancer. Chem Biol, 2004, 11(8): 1043-1051

[19] DuY, KongG, YouX, et al.. Elevation of highly up-regulated in liver cancer (HULC) by hepatitis B virus x protein promotes hepatoma cell proliferation via down-regulating p18. J Biol Chem, 2012, 287(31): 26302-26311

[20] TsangWP, NgEK, NgSS, et al.. Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis, 2010, 31(3): 350-358

[21] BartolomeiMS, ZemelS, TilghmanSM. Parental imprinting of the mouse H19 gene. Nature, 1991, 351(6322): 153-155

[22] AyeshS, MatoukI, SchneiderT, et al.. Possible physiological role of H19 RNA. Mol Carcinog, 2002, 35(2): 63-74

[23] LuoM, LiZ, WangW, et al.. Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. Cancer Lett, 2013, 333(2): 213-221

[24] LuoM, LiZ, WangW, et al.. Upregulated H19 contributes to bladder cancer cell proliferation by regulating ID2 expression. FEBS J, 2013, 280(7): 1709-1716

[25] HaoY, CrenshawT, MoultonT, et al.. Tumour-suppressor activity of H19 RNA. Nature, 1993, 365(6448): 764-767

[26] ZhangL, YangF, YuanJH, et al.. Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma. Carcinogenesis, 2013, 34(3): 577-586

[27] TripathiV, ShenZ, ChakrabortyA, et al.. Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. PLoS Genet, 2013, 9(3): e1003368

[28] BlombergI, HoffmannI. Ectopic expression of Cdc25A accelerates the G(1)/S transition and leads to premature activation of cyclin E- and cyclin A-dependent kinases. Mol Cell Biol, 1999, 19(9): 6183-6194

[29] MolinariM, MercurioC, DominguezJ, et al.. Human Cdc25A inactivation in response to S phase inhibition and its role in preventing premature mitosis. EMBO Rep, 2000, 1(1): 71-79

[30] YangC, LiX, WangY, et al.. Long non-coding RNA UCA1 regulated cell cycle distribution via CREB through PI3-K dependent pathway in bladder carcinoma cells. Gene, 2012, 496(1): 8-16

[31] CohenP, FrameS. The renaissance of GSK3. Nat Rev Mol Cell Biol, 2001, 2(10): 769-776

[32] PucJ, KeniryM, LiHS, et al.. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell, 2005, 7(2): 193-204

[33] ShtivelmanE, SussmanJ, StokoeD. A role for PI3-kinase and PKB activity in the G2/M phase of the cell cycle. Curr Biol, 2002, 12(11): 919-924